RNA Analytical Quality/Resources

  1. Novel Plasmid DNA-Encoded Poly(A) Tails For mRNA Synthesis 4/26/2024

    Here, we evaluate the stability of these variant poly(A) regions and the biological activity of the mRNA containing the variant poly(A) tails made from these templates.

  2. A&M STABTEST Expands Service Offerings In Protein And Oligonucleotide Analysis With LC-MS System 2/22/2022

    CRO upgrades systems to provide regulatory compliance for large-molecule protein analysis, expanding their oligonucleotides capabilities.

  3. Development Of Alternative BCDP Reagents For The Synthesis Of 5' -Terminal Phosphate Oligonucleotides 11/25/2025

    New alternative phosphitylating reagents reduce the safety hazards associated with BCDP, enabling a safer and effective synthesis of key oligonucleotide sequences.

  4. Alternatives To CRISPR-Cas9: Nucleases For Next-Gen Therapy 10/28/2024

    Alternatives to CRISPR-Cas9 address limitations like delivery challenges and off-target effects. Emerging nucleases offer improved specificity, smaller sizes, and therapeutic applications.

  5. The Absolute Essentials Of Manufacturability 11/12/2025

    Learn why integrating Quality by Design (QbD) and Process Analytical Technology (PAT) early on is essential for developing a robust, controlled, and financially viable process.

  6. Accelerating IND-Enabling Studies With Automated Bioanalysis Workflows 9/2/2025

    Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.

  7. Learn How Compliance-Ready LC-MS Workflows for Oligonucleotides Can Expand your Analytical Services Portfolio 2/22/2022

    CMO invests in solution to ensure data integrity and meet regulatory requirements as they expand their oligonucleotide manufacturing and analysis services.

  8. Optimizing mRNA For Success: A Guide To Enhanced Stability, Delivery, And Efficacy 6/11/2024

    RNA offers exciting potential for vaccines, gene therapies, and personalized medicine, but challenges related to stability, delivery, and manufacturing persist.

  9. Advancing RNA-LNP Therapeutics As An Alternative To Viral Vectors 11/17/2025

    RNA-LNP therapeutics offer a flexible, transient alternative to traditional viral vectors for genetic medicine. Learn about the advantages of LNPs in safety, scalability, and payload versatility.

  10. Nucleases - Are They A Problem For NAB Nanosep® Centrifugal Devices? 4/29/2022

    We examine whether the sample tubes and collection tubes of the NAB Nanosep centrifugal devices contain detectable amounts of DNase or RNase.